CClinicalTrials.gg
Enrolling by invitationNCT07798466Updated Sep 1, 2026

Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery

An observational study in Breast Cancer, Breast Reconstruction and Radiotherapy, sponsored by Fudan University. Enrolling by invitation at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Fudan University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
128
Ages
18 Years and older
Sex
Female
01

Study summary

This is a prospective, open-label, controlled clinical trial aiming to investigate the optimal sequencing strategy between immediate autologous tissue breast reconstruction and radiotherapy in breast cancer patients. Eligible participants are female breast cancer patients who have completed neoadjuvant chemotherapy and are scheduled to undergo total mastectomy combined with immediate free abdominal flap (DIEP) breast reconstruction. Participants will be assigned to receive either preoperative radiotherapy followed by reconstruction, or postoperative adjuvant radiotherapy after reconstruction. The primary objectives are to compare surgical safety, oncological safety, patient-reported outcomes (PRO), and aesthetic evaluation between the two radiotherapy sequencing strategies. Secondary objectives include optimizing radiotherapy techniques, radiation doses, and target volume delineation for immediate abdominal free flap reconstruction; exploring the impact of hypofractionated radiotherapy on reconstruction-related complications; investigating the association between multi-omics and immune microenvironment changes and radiotherapy efficacy; and exploring the mechanism by which skin microbiota characteristics affect radiation-induced skin injury through modulation of the skin immune microenvironment. This study hopes to provide clinical evidence for establishing the optimal treatment sequence of immediate breast reconstruction and radiotherapy.

02

Conditions studied

  • Breast Cancer
  • Breast Reconstruction
  • Radiotherapy

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female patients diagnosed with breast cancer who receive immediate autologous-tissue breast reconstruction after mastectomy, with or without postoperative radiotherapy.

Inclusion criteria

  • Aged 18 years or older
  • Female
  • Pathologically confirmed invasive breast cancer prior to surgery
  • Planned to receive neoadjuvant chemotherapy
  • No clinical or radiographic evidence of distant metastasis
  • Meets indication for postmastectomy radiotherapy (PMRT)
  • Willing to undergo immediate autologous free flap breast reconstruction using abdominal tissue
  • Able and willing to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Completed neoadjuvant chemotherapy with no current indication for adjuvant radiotherapy
  • Disease progression during neoadjuvant chemotherapy, failing to complete the planned regimen
  • Pregnant or lactating women
  • History of diabetes mellitus
  • History of heavy smoking
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
128 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pre-operative Radiotherapy Group

    Patients receive pre-operative radiotherapy, followed by immediate DIEP flap breast reconstruction surgery. Post-operative rehabilitation and regular follow-up will be performed

    Procedure: Immediate DIEP flap breast reconstruction · Radiation: Hypofractionated radiotherapy

  • Post-operative Radiotherapy Group

    Patients undergo immediate DIEP flap breast reconstruction surgery first, followed by post-operative radiotherapy. Post-operative rehabilitation and regular follow-up will be performed.

    Procedure: Immediate DIEP flap breast reconstruction · Radiation: Hypofractionated radiotherapy

Interventions

  • ProcedureImmediate DIEP flap breast reconstruction

    Autologous breast reconstruction using deep inferior epigastric perforator (DIEP) flap, performed by experienced plastic surgeons, with standard perforator dissection and microsurgical vascular anastomosis.

  • RadiationHypofractionated radiotherapy

    Standard hypofractionated radiotherapy delivered to the breast region with consistent radiation dose, fractionation protocol and radiotherapy technique for all enrolled patients.

05

What researchers measure

Primary outcomes

  1. Patient-reported breast satisfaction assessed by BREAST-Q 2.0 scale

    Patient-reported outcome (PRO) of breast satisfaction will be measured using the validated Chinese version of BREAST-Q 2.0 questionnaire, including satisfaction with breast appearance, surgical outcome, psychosocial well-being and physical well-being.

    Time frame: 12-month after DIEP flap reconstruction surgery

06

Study locations

1 site
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07798466
Lead sponsor
Fudan University
Responsible party
Jiong Wu (Chief Physician,Professor, Fudan University) — Principal investigator
First posted
Sep 1, 2026
Start date
Sep 1, 2025
Primary completion
Nov 1, 2025
Completion
Nov 1, 2026 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion